KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

A new alternative: inhibiting complement activation in patients with IgA nephropathy.

Jürgen Floege

Kidney Int 105(1) 28-30

PMID38182298
PMCID-
DOI10.1016/j.kint.2023.10.012
发表日期2024-01-05
摘要

摘要

Mesangial complement C3 deposits, reflecting alternative and possibly lectin pathway activation, are characteristic in biopsies of patients with IgA nephropathy (IgAN). A recent randomized controlled trial tested the efficacy and safety of iptacopan, a factor B inhibitor, in patients with IgAN. Iptacopan dose-dependently reduced proteinuria, and there was a pronounced decrease of urinary C5b-9. This offers the perspective of "personalizing" therapy, which would be a unique feature of this novel approach to IgAN. A phase III clinical trial (APPLAUSE-IgAN) is ongoing.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。